PTC Therapeutics | PTCT - Operating Profit



PTC Therapeutics reported $-34858000 in Operating Profit for its fiscal quarter ending in June of 2025.


Operating Profit Change Date
Acadia Pharmaceuticals USD 32.37M 13.08M Jun/2025
Alnylam Pharmaceuticals USD -16199000 34.28M Jun/2025
Amgen USD 2.66B 1.37B Jun/2025
Biogen USD 851.8M 540.6M Jun/2025
BioMarin Pharmaceutical USD 276.89M 52.99M Jun/2025
Cytokinetics USD -111506000 44.12M Jun/2025
Daiichi Sankyo JPY 96.71B 13.1B Jun/2025
Gilead Sciences USD 2.7B 467M Jun/2025
Incyte USD 310.82M 105.66M Jun/2025
Ionis Pharmaceuticals USD 139.84M 285.84M Jun/2025
Ironwood Pharmaceuticals USD 33.22M 7.58M Dec/2024
Novartis USD 4.86B 201M Jun/2025
Pfizer USD 2.6B 1.06B Jun/2025
PTC Therapeutics USD -34858000 1.01B Jun/2025
Roche Holding CHF 4.39B 1.04B Dec/2024
Sarepta Therapeutics USD 115.58M 415.96M Jun/2025
TG Therapeutics USD 34.84M 26.22M Jun/2025
Ultragenyx Pharmaceutical USD -193567000 50.63M Jun/2025
Vertex Pharmaceuticals USD 1.15B 123.1M Jun/2025
Xencor USD -33172000 10.01M Jun/2025